These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 16157744)

  • 1. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity.
    Bermel RA; Puli SR; Rudick RA; Weinstock-Guttman B; Fisher E; Munschauer FE; Bakshi R
    Arch Neurol; 2005 Sep; 62(9):1371-6. PubMed ID: 16157744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis.
    Tjoa CW; Benedict RH; Weinstock-Guttman B; Fabiano AJ; Bakshi R
    J Neurol Sci; 2005 Jul; 234(1-2):17-24. PubMed ID: 15993137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
    Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
    Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis.
    Brass SD; Benedict RH; Weinstock-Guttman B; Munschauer F; Bakshi R
    Mult Scler; 2006 Aug; 12(4):437-44. PubMed ID: 16900757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients.
    Bakshi R; Dmochowski J; Shaikh ZA; Jacobs L
    J Neurol Sci; 2001 Mar; 185(1):19-26. PubMed ID: 11266686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study.
    Bakshi R; Benedict RH; Bermel RA; Caruthers SD; Puli SR; Tjoa CW; Fabiano AJ; Jacobs L
    Arch Neurol; 2002 Jan; 59(1):62-8. PubMed ID: 11790232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
    Zivadinov R; Locatelli L; Cookfair D; Srinivasaraghavan B; Bertolotto A; Ukmar M; Bratina A; Maggiore C; Bosco A; Grop A; Catalan M; Zorzon M
    Mult Scler; 2007 May; 13(4):490-501. PubMed ID: 17463072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 May; 18(1):68. PubMed ID: 29751787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A semiautomated measure of whole-brain atrophy in multiple sclerosis.
    Bermel RA; Sharma J; Tjoa CW; Puli SR; Bakshi R
    J Neurol Sci; 2003 Apr; 208(1-2):57-65. PubMed ID: 12639726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial.
    Lin X; Tench CR; Turner B; Blumhardt LD; Constantinescu CS
    J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1090-4. PubMed ID: 12876240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis.
    Miller DH; Molyneux PD; Barker GJ; MacManus DG; Moseley IF; Wagner K
    Ann Neurol; 1999 Dec; 46(6):850-9. PubMed ID: 10589537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis.
    Ceccarelli A; Filippi M; Neema M; Arora A; Valsasina P; Rocca MA; Healy BC; Bakshi R
    Mult Scler; 2009 Jun; 15(6):678-86. PubMed ID: 19482861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3T deep gray matter T2 hypointensity correlates with disability over time in stable relapsing-remitting multiple sclerosis: a 3-year pilot study.
    Zhang Y; Metz LM; Yong VW; Mitchell JR
    J Neurol Sci; 2010 Oct; 297(1-2):76-81. PubMed ID: 20708201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis.
    Zivadinov R; Bagnato F; Nasuelli D; Bastianello S; Bratina A; Locatelli L; Watts K; Finamore L; Grop A; Dwyer M; Catalan M; Clemenzi A; Millefiorini E; Bakshi R; Zorzon M
    J Neurol Sci; 2004 Aug; 223(2):185-93. PubMed ID: 15337621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.
    Beck RW; Chandler DL; Cole SR; Simon JH; Jacobs LD; Kinkel RP; Selhorst JB; Rose JW; Cooper JA; Rice G; Murray TJ; Sandrock AW
    Ann Neurol; 2002 Apr; 51(4):481-90. PubMed ID: 11921054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode.
    Plavina T; Singh CM; Sangurdekar D; de Moor C; Engle B; Gafson A; Goyal J; Fisher E; Szak S; Kinkel RP; Sandrock AW; Su R; Kieseier BC; Rudick RA
    JAMA Netw Open; 2020 Nov; 3(11):e2016278. PubMed ID: 33151313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
    J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis.
    van den Elskamp IJ; Boden B; Dattola V; Knol DL; Filippi M; Kappos L; Fazekas F; Wagner K; Pohl C; Sandbrink R; Polman CH; Uitdehaag BM; Barkhof F
    Neuroradiology; 2010 Oct; 52(10):875-81. PubMed ID: 20049424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis.
    Neema M; Arora A; Healy BC; Guss ZD; Brass SD; Duan Y; Buckle GJ; Glanz BI; Stazzone L; Khoury SJ; Weiner HL; Guttmann CR; Bakshi R
    J Neuroimaging; 2009 Jan; 19(1):3-8. PubMed ID: 19192042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis.
    Khalid F; Healy BC; Dupuy SL; Chu R; Chitnis T; Bakshi R; Houtchens M
    J Neurol Sci; 2018 Sep; 392():94-99. PubMed ID: 30031994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.